Martin Soekler

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 386 citations

Medicine, Oncology, Radiation Oncology +12

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

Bastian von Tresckow, Annette Plütschow, Michael Fuchs et al. · Journal of Clinical Oncology · 2012 · 314 citations · Full text

Medicine, Oncology, Radiation Oncology +11

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert et al. · The Lancet · 2019 · 253 citations · Full text

Medicine, Oncology, Cancer Immunology +10

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe et al. · Journal of Clinical Oncology · 2019 · 229 citations

Medicine, Nuclear Medicine, Oncology +14

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial

Karolin Behringer, Helen Goergen, Felicitas Hitz et al. · The Lancet · 2014 · 181 citations

Medicine, Oncology, Pharmacology +14